» Articles » PMID: 29947252

The Impact of in Vitro Cell Culture Duration on the Maturation of Human Cardiomyocytes Derived from Induced Pluripotent Stem Cells of Myogenic Origin

Abstract

Ischemic heart disease, also known as coronary artery disease (CAD), poses a challenge for regenerative medicine. iPSC technology might lead to a breakthrough due to the possibility of directed cell differentiation delivering a new powerful source of human autologous cardiomyocytes. One of the factors supporting proper cell maturation is in vitro culture duration. In this study, primary human skeletal muscle myoblasts were selected as a myogenic cell type reservoir for genetic iPSC reprogramming. Skeletal muscle myoblasts have similar ontogeny embryogenetic pathways (myoblasts vs. cardiomyocytes), and thus, a greater chance of myocardial development might be expected, with maintenance of acquired myogenic cardiac cell characteristics, from the differentiation process when iPSCs of myoblastoid origin are obtained. Analyses of cell morphological and structural changes, gene expression (cardiac markers), and functional tests (intracellular calcium transients) performed at two in vitro culture time points spanning the early stages of cardiac development (day 20 versus 40 of cell in vitro culture) confirmed the ability of the obtained myogenic cells to acquire adult features of differentiated cardiomyocytes. Prolonged 40-day iPSC-derived cardiomyocytes (iPSC-CMs) revealed progressive cellular hypertrophy; a better-developed contractile apparatus; expression of marker genes similar to human myocardial ventricular cells, including a statistically significant CX43 increase, an MHC isoform switch, and a troponin I isoform transition; more efficient intercellular calcium handling; and a stronger response to β-adrenergic stimulation.

Citing Articles

Enhancing Maturation and Translatability of Human Pluripotent Stem Cell-Derived Cardiomyocytes through a Novel Medium Containing Acetyl-CoA Carboxylase 2 Inhibitor.

Correia C, Christoffersson J, Tejedor S, El-Haou S, Matadamas-Guzman M, Nair S Cells. 2024; 13(16.

PMID: 39195229 PMC: 11352932. DOI: 10.3390/cells13161339.


Toward the latest advancements in cardiac regeneration using induced pluripotent stem cells (iPSCs) technology: approaches and challenges.

Farboud S, Fathi E, Valipour B, Farahzadi R J Transl Med. 2024; 22(1):783.

PMID: 39175068 PMC: 11342568. DOI: 10.1186/s12967-024-05499-8.


Engineered tissue geometry and Plakophilin-2 regulate electrophysiology of human iPSC-derived cardiomyocytes.

Simmons D, Malayath G, Schuftan D, Guo J, Oguntuyo K, Ramahdita G APL Bioeng. 2024; 8(1):016118.

PMID: 38476404 PMC: 10932571. DOI: 10.1063/5.0160677.


In situ monolayer patch clamp of acutely stimulated human iPSC-derived cardiomyocytes promotes consistent electrophysiological responses to SK channel inhibition.

Butler A, Ascione R, Marrion N, Harmer S, Hancox J Sci Rep. 2024; 14(1):3185.

PMID: 38326449 PMC: 10850090. DOI: 10.1038/s41598-024-53571-6.


hiPSC-derived cardiomyocytes as a model to study the role of small-conductance Ca-activated K (SK) ion channel variants associated with atrial fibrillation.

Babini H, Jimenez-Sabado V, Stogova E, Arslanova A, Butt M, Dababneh S Front Cell Dev Biol. 2024; 12:1298007.

PMID: 38304423 PMC: 10830749. DOI: 10.3389/fcell.2024.1298007.


References
1.
Robertson C, Tran D, George S . Concise review: maturation phases of human pluripotent stem cell-derived cardiomyocytes. Stem Cells. 2013; 31(5):829-37. PMC: 3749929. DOI: 10.1002/stem.1331. View

2.
Burridge P, Keller G, Gold J, Wu J . Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell. 2012; 10(1):16-28. PMC: 3255078. DOI: 10.1016/j.stem.2011.12.013. View

3.
Posnack N, Idrees R, Ding H, Jaimes 3rd R, Stybayeva G, Karabekian Z . Exposure to phthalates affects calcium handling and intercellular connectivity of human stem cell-derived cardiomyocytes. PLoS One. 2015; 10(3):e0121927. PMC: 4370601. DOI: 10.1371/journal.pone.0121927. View

4.
Ahuja P, Zhao P, Angelis E, Ruan H, Korge P, Olson A . Myc controls transcriptional regulation of cardiac metabolism and mitochondrial biogenesis in response to pathological stress in mice. J Clin Invest. 2010; 120(5):1494-505. PMC: 2860901. DOI: 10.1172/JCI38331. View

5.
Olson A, Ledee D, Iwamoto K, Kajimoto M, OKelly Priddy C, Isern N . C-Myc induced compensated cardiac hypertrophy increases free fatty acid utilization for the citric acid cycle. J Mol Cell Cardiol. 2012; 55:156-64. PMC: 3524362. DOI: 10.1016/j.yjmcc.2012.07.005. View